BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1609193)

  • 1. [Ex-vivo treatment of a bone marrow graft].
    Bieva CJ
    Rev Med Brux; 1992 May; 13(5):177-82. PubMed ID: 1609193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies].
    Hervé P; Flesch M
    Nouv Rev Fr Hematol (1978); 1986; 28(2):97-105. PubMed ID: 2942838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
    Gribben JG; Freedman AS; Neuberg D; Roy DC; Blake KW; Woo SD; Grossbard ML; Rabinowe SN; Coral F; Freeman GJ
    N Engl J Med; 1991 Nov; 325(22):1525-33. PubMed ID: 1944436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of monoclonal antibodies to bone marrow transplantation].
    Morishima Y
    Gan To Kagaku Ryoho; 1988 May; 15(5):1693-701. PubMed ID: 3285796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell depletion and allogeneic bone marrow transplantation.
    O'Reilly RJ
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):20-6. PubMed ID: 1615341
    [No Abstract]   [Full Text] [Related]  

  • 9. [In vitro manipulation of bone marrow cells for bone marrow transplantation].
    Morishima Y
    Gan To Kagaku Ryoho; 1988 Nov; 15(11):3034-43. PubMed ID: 3056275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
    Casorati G; Locatelli F; Pagani S; Garavaglia C; Montini E; Lisini D; Turin I; Rossi F; Dellabona P; Maccario R; Montagna D
    Exp Hematol; 2005 Feb; 33(2):212-8. PubMed ID: 15676215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia.
    Champlin R; Giralt S; Przepiorka D; Ho W; Lee K; Gajewski J; Nimer S; Andersson B; Wallerstein R; Ippolito C
    Prog Clin Biol Res; 1992; 377():385-94; discussion 395-8. PubMed ID: 1438435
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
    Gowing H; Braakman E; Hagenbeek A; Lawler M; McCann SR; Pamphilon DH; Martens AC
    Bone Marrow Transplant; 1998 Apr; 21(8):801-7. PubMed ID: 9603404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous bone marrow transplantation for leukemia.
    Stuart RK
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
    Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory control in predicting clinical efficacy of T cell-depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis.
    Marciniak E; Romond EH; Thompson JS; Henslee PJ
    Bone Marrow Transplant; 1988 Nov; 3(6):589-98. PubMed ID: 3063328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allograft and autograft purging using immunotoxins in clinical bone marrow transplantation for hematologic malignancies.
    Uckun FM; Myers DE
    J Hematother; 1993; 2(2):155-63. PubMed ID: 7921971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.